河南翔宇医疗设备股份有限公司 2024 年度独立董事述职报告 本人作为河南翔宇医疗设备股份有限公司（以下简称"公司"）独立董事， 2024年任职期间严格依照《公司法》、《证券法》、《上市公司治理准则》、《上 市公司独立董事管理办法》等法律规定、规范性文件以及《公司章程》、《独立 董事工作制度》等有关规定和要求，独立履行职责，及时了解公司的生产经营情 况及发展情况，准时出席公司股东大会、董事会及专门委员会会议，充分发挥了 独立董事的作用，有效维护了公司、全体股东尤其是中小股东的合法权益。现将 本人2024年任职期间履职情况报告如下： 一、独立董事的基本情况 2024年12月，公司第二届董事会任期届满，本人和王珏教授因任期届满6年， 不再担任公司独立董事，公司第三届董事会独立董事由刘振教授和燕铁斌教授担 任。 二、独立董事年度履职概况 （一）出席会议及表决情况 1、出席股东大会、董事会情况 （一）个人工作履历、专业背景以及兼职情况 叶忠明，1968年出生，硕士研究生学历，教授（二级），中原教育教学领军 人才，河南省教学名师，中国注册会计师，中国国籍，无境外永久居留权。1989 年7月至今历任郑州航空工业管理学院助 ...

本人作为河南翔宇医疗设备股份有限公司（以下简称"公司"）独立董事， 2024年任职期间严格依照《公司法》、《证券法》、《上市公司治理准则》、《上 市公司独立董事管理办法》等法律规定、规范性文件以及《公司章程》、《独立 董事工作制度》等有关规定和要求，独立履行职责，及时了解公司的生产经营情 况及发展情况，准时出席公司股东大会、董事会及专门委员会会议，充分发挥了 独立董事的作用，有效维护了公司、全体股东尤其是中小股东的合法权益。现将 本人2024年任职期间履职情况报告如下： 一、独立董事的基本情况 2024年12月，公司第二届董事会任期届满，本人和叶忠明教授因任期届满6 年，不再担任公司独立董事，公司第三届董事会独立董事由刘振教授和燕铁斌教 授担任。 河南翔宇医疗设备股份有限公司 2024 年度独立董事述职报告 （一）个人工作履历、专业背景以及兼职情况 王珏，1955年出生，博士学历，康复科学与技术专业，中国国籍，无境外永 久居留权。2001年6月至2022年10月担任西安交通大学生命科学与技术学院教授、 博导、生物医学工程研究所所长等职，曾任美国匹兹堡大学健康与康复科学学院 兼职教授。现为西安交通大学生命科学与 ...

河南翔宇医疗设备股份有限公司 舆情管理制度 第一章 总则 第一条 为提高河南翔宇医疗设备股份有限公司（以下简称"公司"）应对各类舆情 的能力，建立快速反应和应急处置机制，充分发挥互联网互动优势，正确把 握和引导网络舆论导向，及时、妥善处理各类舆情对公司股价、商业信誉及 正常经营活动造成的影响，切实保护投资者合法权益，根据《上海证券交易 所科创板股票上市规则》及相关法律法规和《河南翔宇医疗设备股份有限公 司章程》（以下简称"《公司章程》"）等相关规定，结合公司实际情况， 制定本制度。 第二条 本制度所称舆情包括： 第三条 舆情信息的分类： 第二章 舆情管理的组织体系及其工作职责 第四条 公司应对各类舆情实行统一领导、统一组织、快速反应、协同应对的方针， 1 第九条 舆情信息应对及处理原则： (一) 快速反应、迅速行动。公司应保持对舆情信息的敏感度，快速反应、 迅速行动，及时制定相应的舆情应对方案。 第十条 舆情信息的报告流程： 3 (二) 协调组织、真诚沟通。公司在舆情处理的过程中，应协调和组织好对 外宣传工作，严格保证对外信息的一致性，同时要自始至终保持与媒 体、投资者等相关方的真诚沟通。在不违反信息披露规定 ...

河南翔宇医疗设备股份有限公司 2024 年度独立董事述职报告 本人作为河南翔宇医疗设备股份有限公司（以下简称"公司"）独立董事， 2024年任职期间严格依照《公司法》、《证券法》、《上市公司治理准则》、《上 市公司独立董事管理办法》等法律规定、规范性文件以及《公司章程》、《独立 董事工作制度》等有关规定和要求，独立履行职责，及时了解公司的生产经营情 况及发展情况，准时出席公司股东大会、董事会及专门委员会会议，充分发挥了 独立董事的作用，有效维护了公司、全体股东尤其是中小股东的合法权益。现将 本人2024年任职期间履职情况报告如下： 一、独立董事的基本情况 2024年12月，公司第二届董事会任期届满，公司及时选举了第三届董事会成 员，叶忠明教授和王珏教授因任期届满不再担任公司独立董事，本人和燕铁斌教 授被选举为第三届董事会的独立董事。截至2024年12月31日，公司共有独立董事 2名。 （一）个人工作履历、专业背景以及兼职情况 刘振，1969年出生，管理学博士，中国国籍，无境外永久居留权，现任郑州 航空工业管理学院商学院教授。河南省工商管理重点学科带头人、河南省高校科 技创新人才、河南省教育厅学术技术带头人，河 ...

Dividend and Profit Distribution - The company plans to distribute a cash dividend of 2.40 CNY per 10 shares, totaling approximately 37,004,880.00 CNY, which represents 35.95% of the net profit attributable to shareholders for the fiscal year 2024[5]. - The total amount for cash dividends and share repurchases is 114,577,116.10 CNY, accounting for 111.30% of the net profit attributable to shareholders for the fiscal year 2024[5]. - The company has implemented a share repurchase program totaling 77,572,236.10 CNY, excluding transaction fees[5]. - No capital reserve fund transfer to increase share capital or stock dividends will be conducted this year, with undistributed profits carried forward to future years[6]. - The cash dividend payout ratios for 2022, 2023, and 2024 are 30.14%, 36.36%, and 35.95%, respectively, with a planned cash dividend of 37.0049 million yuan for 2024[52]. Financial Performance - The company reported a revenue increase of 15% year-over-year, reaching $1.2 billion in Q3 2023[17]. - The company's operating revenue for 2024 was CNY 743.53 million, a slight decrease of 0.17% compared to CNY 744.81 million in 2023[24]. - The net profit attributable to shareholders for 2024 was CNY 102.94 million, down 54.68% from CNY 227.14 million in 2023[27]. - The basic earnings per share decreased by 54.17% to CNY 0.66 in 2024 from CNY 1.44 in 2023[26]. - The company's total assets increased by 12.95% to CNY 2.93 billion in 2024 from CNY 2.59 billion in 2023[25]. - The net cash flow from operating activities for 2024 was CNY 178.59 million, a decrease of 21.64% from CNY 227.91 million in 2023[24]. - The company's net assets attributable to shareholders decreased by 2.50% year-on-year, totaling 2,038.68 million RMB[36]. - The company achieved operating revenue of 743.53 million RMB, a year-on-year decrease of 0.17%[36]. - The gross margin for the main business in 2024 was 67.41%, a decrease of 1.87 percentage points compared to 2023[160]. Research and Development - Research and development expenses accounted for 20.45% of operating revenue in 2024, an increase of 6.12 percentage points from 14.33% in 2023[26]. - The company achieved a total of 152,022,069.57 CNY in research and development (R&D) expenses, marking a 42.41% increase compared to the previous year[120]. - The company has added 467 new patents, bringing the total to 1,921, including 107 new invention patents[37]. - The company is investing $50 million in R&D for AI-driven rehabilitation technologies to enhance treatment efficiency[17]. - The company has established a research institute for rehabilitation medical devices in collaboration with Xi'an Jiaotong University[115]. - The company has participated in 11 national key research and development programs, showcasing its innovation capabilities in the rehabilitation medical field[81]. - The company has developed a "Venous Thromboembolism Risk Assessment and Prevention Software System V1.0," which has been recognized as a first edition software product in Henan Province for 2024[138]. Market Expansion and Strategy - Market expansion plans include entering three new countries by Q2 2024, aiming for a 30% increase in international sales[17]. - The company is focused on expanding its market presence and enhancing its product offerings in rehabilitation and AI medical fields[45]. - The company is expanding its sales network domestically and internationally, particularly targeting the "Belt and Road" regions, and is optimizing its export product lineup[189][196]. - The company is actively pursuing partnerships and collaborations to enhance its technological capabilities and market reach in the healthcare sector[113]. - The company has accelerated its international expansion, focusing on countries along the "Belt and Road" initiative, achieving growth in export business with products sold to over 30 countries and regions, including Southeast Asia and the Middle East[46]. Product Development and Innovation - New product launches included a state-of-the-art rehabilitation device, projected to generate $200 million in sales over the next year[17]. - The company launched several new products, including infrared thermal radiation therapy devices and brain-controlled products, to meet clinical needs[45]. - The company is focused on developing new technologies and products to enhance rehabilitation outcomes, including systems for balance training and assessment[58]. - The company has developed a series of innovative rehabilitation technologies, including an intelligent mirror distance measuring device and a brain function assessment system, aimed at enhancing patient recovery and cognitive function[111]. - The company is enhancing its capabilities in rehabilitation services for disabled individuals through innovative manufacturing processes[10]. Corporate Governance and Compliance - The board of directors and supervisory board members have confirmed the authenticity, accuracy, and completeness of the annual report[3]. - The company has received a standard unqualified audit report from the accounting firm[4]. - The company does not have any special arrangements for corporate governance[7]. - The company has not faced any non-operating fund occupation by controlling shareholders or related parties[9]. - The company has not violated any decision-making procedures for providing guarantees[9]. Risks and Challenges - The company has outlined potential risks in its operations, which investors should be aware of[3]. - The company faces risks from intensified market competition and potential price reductions due to centralized procurement policies in the rehabilitation medical device sector[156]. - The company has faced risks related to management due to rapid business expansion, necessitating improvements in internal controls[151]. - The company is at risk of losing core technological advantages if competitors achieve significant breakthroughs in technology[149]. Customer Engagement and Satisfaction - Customer satisfaction ratings improved to 90%, reflecting the success of recent service enhancements[17]. - The company has established a comprehensive clinical lecturer team and after-sales service system to meet diverse consumer needs from top-tier hospitals to grassroots health clinics[146]. - The company has a proactive after-sales service strategy, with engineers stationed in all 31 provincial regions, enhancing customer engagement and identifying new equipment needs[147]. Industry Trends and Outlook - The rehabilitation medical service market in China is projected to reach 268.6 billion RMB by 2025, with a CAGR of approximately 38.5% from 2021 to 2025[183]. - The increasing demand for rehabilitation services is driven by an aging population and rising chronic diseases, creating significant growth opportunities for the company[182]. - The global rehabilitation treatment demand has increased by 63% since 1990, with 2.41 billion people potentially benefiting from such treatments[76]. - China's rehabilitation medical industry market size is projected to exceed 200 billion yuan by 2025[76].

Financial Performance - The company's operating revenue for Q1 2025 was ¥186,048,007.84, representing a 10.02% increase compared to ¥169,097,488.82 in the same period last year[4] - Net profit attributable to shareholders decreased by 41.26% to ¥22,951,013.60 from ¥39,073,828.52 year-on-year[4] - The net profit after deducting non-recurring gains and losses fell by 48.72% to ¥18,708,109.46 compared to ¥36,482,745.51 in the previous year[4] - Basic earnings per share decreased by 40.00% to ¥0.15 from ¥0.25 year-on-year[4] - Net profit for Q1 2025 was ¥22,372,121.70, a decrease of 42.3% from ¥38,725,982.66 in Q1 2024[21] Research and Development - Research and development expenses totaled ¥38,245,456.20, an increase of 29.37% from ¥29,562,422.95, accounting for 20.56% of operating revenue[5] - The company is focusing on enhancing its capabilities in brain-computer interfaces and rehabilitation robotics, which has led to increased R&D and sales expenses[7] - Research and development expenses for Q1 2025 amounted to ¥38,245,456.20, an increase of 29.4% from ¥29,562,422.95 in Q1 2024[20] Cash Flow and Financing Activities - The net cash flow from operating activities was ¥20,844,216.27, up 20.52% from ¥17,295,631.36 in the previous year[4] - Cash inflow from operating activities totaled ¥238,724,034.47 in Q1 2025, compared to ¥175,052,571.80 in Q1 2024[22] - The company incurred a net cash outflow from investing activities of ¥184,841,430.36 in Q1 2025, compared to a net outflow of ¥129,823,616.21 in Q1 2024[22] - Cash inflow from financing activities totaled $508,939,160, an increase from $267,000,000 in the previous period, representing a 90.5% growth[24] - Cash outflow from financing activities amounted to $316,171,080.96, compared to $61,860,373.09 previously, indicating a significant increase[24] - Net cash flow from financing activities was $192,768,079.04, slightly down from $205,139,626.91 in the prior period[24] - The net increase in cash and cash equivalents was $28,790,032.07, a decrease from $92,604,587.47 year-over-year[24] - The ending balance of cash and cash equivalents was $731,702,584.50, compared to $744,371,900.04 in the previous period[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,106,935,592.27, a 6.12% increase from ¥2,927,874,338.81 at the end of the previous year[5] - The total current assets increased to approximately RMB 1.30 billion as of March 31, 2025, compared to RMB 1.14 billion at the end of 2024, representing a growth of about 14%[15] - The company reported a short-term loan of approximately RMB 580.20 million, an increase from RMB 354.10 million in the previous period, reflecting a rise of about 64%[16] - The company’s total liabilities increased to approximately RMB 919.14 million, compared to RMB 734.71 million, marking an increase of about 25%[16] - Total liabilities increased to ¥1,058,127,258.99 in the current period from ¥873,096,802.37 in the previous period[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,895[9] - Total equity attributable to shareholders decreased to ¥2,033,288,822.86 from ¥2,038,679,134.12[17] Awards and Recognition - The company was recognized as a "National Specialized and Innovative" small giant enterprise in the sports field[12] - The company received the "Innovation Development Practice Base" award in the medical and health industry[12] - The company participated in projects that won significant awards, including the first prize in the Anhui Provincial Science and Technology Progress Award for a wearable rehabilitation robot system[12] - The company achieved a total of 359 medical device registration certificates and filings, with 13 new additions during the reporting period[12] - The company obtained 52 new patents, including 11 invention patents, bringing the total to 1,954 patents[12]

关于对河南翔宇医疗设备股份有限公司 控股股东及其他关联方占用资金情况的 专项审计说明 关于对河南翔宇医疗设备股份有限公司 控股股东及其他关联方 占用资金情况的专项审计说明 | 目 录 | 页 J/K | | --- | --- | | 关于对河南翔宇医疗设备股份有限公司非经营性 | 1-2 | | 资金占用及其他关联资金往来情况的专项报告 | | | 非经营性资金占用及其他关联资金往来情况汇总 | 1-2 | | 表 | | 立信会计师事务所(特殊普通合伙) IBDO 2 BDO CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS LLP 关于河南翔宇医疗设备股份有限公司 非经营性资金占用及其他关联资金往来情况 的专项报告 信会师报字[2025]第 ZE10217 号 河南翔宇医疗设备股份有限公司全体股东: 信会师报字[2025]第 ZE10217 号 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进 -- 我们审计了河南翔宇医疗设备股份有限公司(以下简称"翔宇公 司")2024年度的财务报表,包括 2024年 ...

公司代码：688626 公司简称：翔宇医疗 河南翔宇医疗设备股份有限公司 2024年度内部控制评价报告 河南翔宇医疗设备股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 3. 是否发现非财务报告内部控制重大缺陷 □是 √否 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性， ...

根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理 准则》《国有企业、上市公司选聘会计师事务所管理办法》《上海证券交易所上 市公司自律监管指引第 1 号——规范运作》和河南翔宇医疗设备股份有限公司 （以下简称"公司"）的《公司章程》《董事会审计委员会议事规则》等规定和 要求，董事会审计委员会本着勤勉尽责的原则，恪尽职守，认真履职。现将董事 会审计委员会对会计师事务所 2024 年度履行监督职责的情况汇报如下： 一、2024 年年审会计师事务所基本情况 河南翔宇医疗设备股份有限公司 董事会审计委员会关于对公司 2024 年度会计师事务所 履行监督职责情况的报告 1、会计师事务所基本情况 立信会计师事务所由我国会计泰斗潘序伦博士于 1927 年在上海创建，1986 年复办，2010 年成为全国首家完成改制的特殊普通合伙制会计师事务所，注册 地址为上海市，首席合伙人为朱建弟先生。立信会计师事务所是国际会计网络 BDO 的成员所，长期从事证券服务业务，新证券法实施前具有证券、期货业务许 可证，具有 H 股审计资格，并已向美国公众公司会计监督委员会（PCAOB）注册 登记。 截至 2024 年末，立信会 ...

证券代码：688626 证券简称：翔宇医疗 公告编号：2025-027 河南翔宇医疗设备股份有限公司 关于将剩余超募资金用于其他在建项目的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 项目名称："康复医疗器械产业园"项目研发中心楼、综合楼及相关 配套。 投资金额及资金来源：研发中心楼、综合楼及相关配套拟投资金额 30,161.71 万元（最终金额以实际投资为准），其中拟使用超募资金 7,911.96 万元（含扣除手续费后的利息收入、现金管理收益等，实际金额以资金转出当日 超募账户余额为准），剩余部分由公司全资子公司河南瑞贝塔医疗科技有限公司 （以下简称"瑞贝塔"）使用自筹资金投入。 一、募集资金基本情况 根据中国证券监督管理委员会于 2021 年 1 月 26 日出具的《关于同意河南翔 宇医疗设备股份有限公司首次公开发行股票注册的批复》（证监许可〔2021〕254 号），公司获准向社会公众发行人民币普通股（A 股）40,000,000 股，每股发行 价格为人民币 28.82 元，本次发行募集资金总额 ...